13,150 Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,150 shares of the company’s stock, valued at approximately $45,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XERS. R Squared Ltd purchased a new stake in Xeris Biopharma in the 4th quarter worth about $42,000. Cibc World Markets Corp bought a new position in Xeris Biopharma in the 4th quarter worth about $44,000. Virtu Financial LLC bought a new position in Xeris Biopharma in the 4th quarter worth about $58,000. Russell Investments Group Ltd. grew its stake in Xeris Biopharma by 1,496.3% in the 4th quarter. Russell Investments Group Ltd. now owns 17,974 shares of the company’s stock worth $61,000 after acquiring an additional 16,848 shares in the last quarter. Finally, Sunpointe LLC bought a new position in Xeris Biopharma in the 4th quarter worth about $71,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Beth Hecht sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 6.47% of the company’s stock.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $4.64 on Thursday. The firm’s 50 day moving average price is $4.71 and its 200-day moving average price is $3.88. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.86 and a 52-week high of $6.07. The company has a market cap of $725.63 million, a PE ratio of -10.31 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. On average, analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on XERS. Jefferies Financial Group restated a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Oppenheimer upped their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Piper Sandler restated a “neutral” rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners upped their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th. Finally, Craig Hallum upped their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.